Clinical trials: Proof of Concept
Lupus Erythematosus, Systemic
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in…
- Trial name
- NCT02349061
- Testing
- Ustekinumab IV, Ustekinumab SC, Concomitant Medication
- Where
- 43 sites in United States, Argentina and 7 more
- Volunteers
- 102 people
- Sponsor
- Janssen Research & Development, LLC
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Neuropathic Pain in Cancer
Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer
The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the neuropathic pain associated with cancer, in addition to explore the effective concentration of NPC-06.
- Trial name
- NCT03773055
- Testing
- NPC-06
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Nobelpharma
Circadian Rhythm Disorders
A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder
The main purpose of this study was to demonstrate that LML134 can increase wakefulness compared to placebo in patients with shift work disorder (SWD) measured by objective and subjective endpoints of wakefulness, i.e.
- Trial name
- NCT03141086
- Testing
- LML134
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Blood Pressure
WBPS A Prospective, Method Comparison, Proof of Concept Study
The study will evaluate the accuracy of BP measurements by a new algorithm to be embedded to the existing CE-marked WinPack device, compared to two reference devices (one oscillometric and one volume-clamp device), in healthy…
- Trial name
- WBPS (NCT02934386)
- Testing
- WinMedical WinPack device
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Hearing Loss
Evaluating an Audiology Text-Message Protocol to Support Hearing Aid Use in NHS Adult Audiology Patients
Over 18 million adults in the United Kingdom have significant hearing loss, linked to isolation, depression and comorbidities. Hearing aids are the main management option yet are frequently unused (~23%) or used irregularly…
- Trial name
- NCT07146607
- Testing
- Audiology text-message protocol
- Where
- 3 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- WSAUD A/S
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Ocular Surface Disease
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28 days in ameliorating adverse ocular side effects in patients under ongoing treatment with glaucoma medications.
- Trial name
- NCT02656394
- Testing
- GL101
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Glia, LLC
Mild to Moderate Atopic Dermatitis
Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
Atopic dermatitis (AD) is a chronic or chronic recurring inflammatory skin disorder. Patients suffer from eczema and often severe pruritus on the affected skin, as well as from frequent complications and secondary infections.
- Trial name
- NCT02079688
- Testing
- SB011, 2 % (Water/Oil/Water) emulsion of hgd40, Multiple W/O/W formulation, active ingredient-free vehicle
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Cystitis, Interstitial, Urinary Bladder Disease
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.
- Conditions
- Cystitis, Interstitial, Urinary Bladder Disease, Pain, Urologic Diseases
- Trial name
- AMARANTH (NCT01613586)
- Testing
- ASP3652
- Where
- 60 sites in Belgium, Czechia and 10 more
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Europe B.V.
Myasthenia Gravis
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
Study CV-0002 is the first clinical trial administering CV-MG01 in humans. This clinical trial is a safety and proof-of-concept study (proof of mechanism of action) intended to assess the safety, tolerability and immunogenic…
- Trial name
- NCT02609022
- Testing
- CV-MG01
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- CuraVac
Urinary Tract Infections
Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)
To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI.
- Trial name
- FLUT (NCT00722735)
- Testing
- Finafloxacin, Ciprofloxacin
- Where
- 2 sites in Germany, Singapore
- Volunteers
- 36 people
- Sponsor
- MerLion Pharmaceuticals GmbH
Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or intolerant to oral aminosalicylates.
- Trial name
- NCT06398808
- Testing
- Arm1, Arm 2
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Schizophrenia, Schizoaffective Disorder
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00734435
- Testing
- zonisamide SR plus olanzapine
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Orexigen Therapeutics, Inc
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.
- Trial name
- NCT00826514
- Testing
- Tanezumab
- Where
- 44 sites in United States, Canada and 3 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Osteoarthritis of Knee
Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis.
3VM1001 is a topical cream that may be useful for the treatment of chronic osteoarthritis of the knee. This proof of concept study is a randomized, placebo-controlled, double-blind study to compare treatment with 3VM1001 cream to…
- Trial name
- NCT02332148
- Testing
- 3VM1001
- Volunteers
- 50 people
- Sponsor
- CDA Research Group, Inc.
Heart Failure
A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure
The primary objective of the study is to compare relative changes in blood N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after 30 days of treatment in participants with worsening heart failure (WHF), who are…
- Trial name
- NCT06795399
- Testing
- OPC-131461
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Body Odor
A Third Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults
The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70…
- Trial name
- NCT07726238
- Testing
- NOBO postbiotic
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingdom
Diarrhoea, Clostridium Difficile
Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection
Clostridium difficile (C. difficile) can cause symptoms ranging from mild diarrhea to life-threatening colitis. Illness from C. difficile most commonly affects patients in hospitals and long-term care facilities and typically…
- Trial name
- NCT01570634
- Testing
- Calcium Aluminosilicate Anti-Diarrheal (CASAD)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Salient Pharmaceuticals Incorporated
Acute Myeloid Leukemia
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy.
- Trial name
- NCT05155709
- Testing
- siremadlin, venetoclax, azacitidine
- Where
- 10 sites in United States, Hong Kong and 5 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals